| Title | [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy] | | Author(s) | Zhu L, Yan B, Ma W | | Institution | Beijing Institute of Tuberculosis and Thoracic Tumor, Beijing 101149. | | Source | Zhonghua Jie He He Hu Xi Za Zhi 1998 Nov; 21(11):645-7. | | MeSH | Adolescent
Adult
Aged
Antitubercular Agents
Drug Therapy, Combination
English Abstract
Female
Humans
Isoniazid
Male
Middle Aged
Pyrazinamide
Rifampin
Tuberculosis, Pulmonary
| | Abstract | OBJECTIVE: To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China.
METHOD: Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation.
RESULT: The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively.
CONCLUSION: Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China. | | Language | chi | | Pub Type(s) | Clinical Trial
Journal Article
Randomized Controlled Trial
| | PubMed ID | 11477887 |
|
